The American Joint Committee on Cancer (AJCC) introduced a new brand identity and logo at its 2013 annual meeting, which took place in September in Chicago, IL. The new AJCC identity, which focuses on leadership, education, and trust, also includes a new website and an AJCC Twitter account.
“I think we have created something that is distinctive and really represents us well,” said Carolyn Compton, MD, PhD, FCAP, outgoing AJCC Chair. Dr. Compton noted that the new identity is intended to revitalize the AJCC’s brand personality and to establish a contemporary look that will draw an immediate response when viewed.
The new AJCC logo, which represents the energy and expertise of AJCC volunteers who work to improve the care of cancer patients, consists of a torch with a flame and a multicolored helix spiraling around the torch. Dr. Compton noted that the torch is a symbol of knowledge and leadership, the flame for providing light and a path to knowledge, the colors for progression and melding of different elements or groups coming together to find solutions, and the helix to signify DNA and the AJCC’s commitment to science.
“We also wanted to convey a very focused message. We wanted to make certain that people understood our objectives as being the premier educational source for integrating staging and the hub for the cancer staging community,” Dr. Compton said.
“I have learned that cancer is in fact a complex, adaptive system—the opposite of a system which is linear and operates by Newtonian equations,” Dr. Compton added.
The AJCC continues to collaborate with the leading experts across all research disciplines in order to develop and apply the academically rigorous and scientifically validated standards for cancer. View the AJCC’s new website.
Established in 1959, the AJCC, which is administered by the American College of Surgeons, formulates and publishes systems of classification of cancer, including staging and end-results reporting, that will be acceptable to and used by the medical profession for selecting the most effective treatment, determining prognosis, and continuing evaluation of cancer control measures.